EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Pharmacokinetic profile of orally administered itraconazole in human skin



Pharmacokinetic profile of orally administered itraconazole in human skin



Journal of the American Academy of Dermatology 18(2 part 1): 263-268



The skin kinetics in human volunteers were studied after administration of 100 (2 volunteers) and 200 (1 volunteer) mg itraconazole daily. From day 7 onward, tissue levels in the beard region and on the back were consistently higher than the corresponding plasma levels.

Accession: 001653464

Download citation: RISBibTeXText

PMID: 2831254

DOI: 10.1016/S0190-9622(88)70037-7

Download PDF Full Text: Pharmacokinetic profile of orally administered itraconazole in human skin



Related references

Pharmacokinetic Profile of Orally Administered Scyllo-Inositol Elnd005 in Plasma, Cerebospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects. 2013

Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. International Journal of Clinical Pharmacology, Therapy, and Toxicology 21(11): 581-586, 1983

Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. Journal of Clinical Pharmacology 46(2): 172-178, 2006

Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid. Antimicrobial Agents and ChemoTherapy 47(5): 1771-1773, 2003

On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human. Cephalalgia 3 Suppl 1: 146-150, 1983

Intermittent-pulse treatment of onychomycosis with orally administered itraconazole. Hunan Yi Ke Da Xue Xue Bao 24(1): 71-73, 2002

Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. European Journal of Clinical Pharmacology 71(3): 321-327, 2016

Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. European Journal of Clinical Pharmacology 66(4): 387-397, 2010

Dermatophytoses treated with itraconazole r 51211 administered orally in doses of 100 milligrams per day for 2 weeks. Chronica Dermatologica 1(1): 91-96, 1991

Bioequivalence of orally administered generic, compounded, and innovator-formulated itraconazole in healthy dogs. Journal of Veterinary Internal Medicine 28(1): 72-77, 2014

A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. Journal of Clinical Pharmacology 38(7): 593-602, 1998

Orally administered ethanol: transepidermal pathways and effects on the human skin barrier. Archives of Dermatological Research 296(7): 332-338, 2005

Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Reviews of Infectious Diseases 9 Suppl 1: S15-S32, 1987

Successful treatment of invasive pulmonary aspergillosis in chronic granulomatous disease with orally administered itraconazole suspension. American Journal of Respiratory and Critical Care Medicine 149(1): 239-241, 1994